AbbVie signed a licensing deal giving it ex‑China rights to Zelgen Biopharmaceuticals’ trispecific T‑cell engager alveltamig (ZG‑006), paying $100 million up front with up to $1.075 billion in further milestones and tiered royalties. The agreement, announced Dec. 31, 2025, positions AbbVie to commercialize a DLL3‑targeting multispecific agent outside China while Zelgen retains China rights. Alveltamig targets DLL3, a protein expressed in a high proportion of small‑cell lung cancers. AbbVie and Zelgen framed the transaction as a strategic move to expand multispecific T‑cell engager portfolios amid renewed interest in T‑cell redirection approaches. The deal structure balances near‑term capital to Zelgen with large potential downstream payouts tied to development, regulatory and commercial success.